Jingyi Gan1, Fanwei Meng1, Xin Zhou1, Chan Li1, Yixin He1, Xiaoping Zeng1, Xingen Jiang1, Jia Liu1, Guifang Zeng1, Yunxia Tang1, Muyun Liu1, Randall J Mrsny2, Xiang Hu3, Jifan Hu4, Tao Li5. 1. Shenzhen Beike Cell Engineering Research Institute, Yuanxing Science and Technology Building, Nanshan, Shenzhen, China. 2. GMR Epigenetics, Palo Alto, California, USA; Department of Pharmacy & Pharmacology, University of Bath, Bath, England. 3. Shenzhen Beike Cell Engineering Research Institute, Yuanxing Science and Technology Building, Nanshan, Shenzhen, China. Electronic address: huxiang@beike.cc. 4. VA Palo Alto Health Care System, Stanford University Medical School, Palo Alto, California, USA; GMR Epigenetics, Palo Alto, California, USA. Electronic address: jifan@stanford.edu. 5. Shenzhen Beike Cell Engineering Research Institute, Yuanxing Science and Technology Building, Nanshan, Shenzhen, China. Electronic address: litao@beike.cc.
Abstract
BACKGROUND AIMS: Acute radiation syndrome (ARS) leads to pancytopenia and multi-organ failure. Transplantation of hematopoietic stem cells provides a curative option for radiation-induced aplasia, but this therapy is limited by donor availability. METHODS: We examined an alternative therapeutic approach to ARS with the use of human extracellular superoxide dismutase (ECSOD)-modified umbilical cord mesenchymal stromal cells (UCMSCs). This treatment combines the unique regenerative role of UCMSCs with the anti-oxidative activity of ECSOD. RESULTS: We demonstrated that systemically administered ECSOD-UCMSCs are able to protect mice from sub-lethal doses of radiation and improve survival by promoting multilineage hematopoietic recovery. The therapeutic effect of this treatment is related to the decrease in radiation-induced O(2)(-) and apoptosis. CONCLUSIONS: Our data highlight the clinical potential of this two-pronged approach to the treatment of ARS, thereby serving as a rapid and effective first-line strategy to combat the hematopoietic failure resulting from a radiation accident, nuclear terrorism and other radiologic emergencies.
BACKGROUND AIMS: Acute radiation syndrome (ARS) leads to pancytopenia and multi-organ failure. Transplantation of hematopoietic stem cells provides a curative option for radiation-induced aplasia, but this therapy is limited by donor availability. METHODS: We examined an alternative therapeutic approach to ARS with the use of humanextracellular superoxide dismutase (ECSOD)-modified umbilical cord mesenchymal stromal cells (UCMSCs). This treatment combines the unique regenerative role of UCMSCs with the anti-oxidative activity of ECSOD. RESULTS: We demonstrated that systemically administered ECSOD-UCMSCs are able to protect mice from sub-lethal doses of radiation and improve survival by promoting multilineage hematopoietic recovery. The therapeutic effect of this treatment is related to the decrease in radiation-induced O(2)(-) and apoptosis. CONCLUSIONS: Our data highlight the clinical potential of this two-pronged approach to the treatment of ARS, thereby serving as a rapid and effective first-line strategy to combat the hematopoietic failure resulting from a radiation accident, nuclear terrorism and other radiologic emergencies.
Authors: Giuseppe Lia; Clara Di Vito; Marco Cerrano; Lucia Brunello; Francesca Calcaterra; Marta Tapparo; Luisa Giaccone; Domenico Mavilio; Benedetto Bruno Journal: Front Immunol Date: 2020-03-20 Impact factor: 7.561
Authors: Somaiah Chinnapaka; Katherine S Yang; Yasamin Samadi; Michael W Epperly; Wen Hou; Joel S Greenberger; Asim Ejaz; J Peter Rubin Journal: Stem Cells Transl Med Date: 2021-03-16 Impact factor: 6.940